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Abstract
Background: Despite demonstrated benefits and World Health Organization (WHO) endorsement, parenteral
artesunate is the recommended treatment for patients with severe Plasmodium falciparum malaria in only one fifth
of endemic countries. One possible reason for this slow uptake is that a treatment course of parenteral artesunate is
costlier than quinine and might, therefore, pose a substantial economic burden to health care systems. This analysis
presents a detailed account of the resources used in treating falciparum malaria by either parenteral artesunate or
quinine in a hospital on the Thai-Myanmar border.
Methods: The analysis used data from four studies, with random allocation of inpatients with falciparum malaria to
treatment with parenteral artesunate or quinine, conducted in Mae Sot Hospital, Thailand from 1995 to 2001.
Detailed resource use data were collected during admission and unit costs from the 2008 hospital price list were
applied to these. Total admission costs were broken down into five categories: 1) medication; 2) intravenous fluids;
3) disposables; 4) laboratory tests; and 5) services.
Results: While the medication costs were higher for patients treated with artesunate, total admission costs were
similar in those treated with quinine, US$ 243 (95% CI: 167.5-349.7) and in those treated with artesunate US$ 190
(95% CI: 131.0-263.2) (P = 0.375). For cases classified as severe malaria (59%), the total cost of admission was US$ 298
(95% CI: 203.6-438.7) in the quinine group as compared with US$ 284 (95% CI: 181.3-407) in the artesunate group
(P = 0.869).
Conclusion: This analysis finds no evidence for a difference in total admission costs for malaria inpatients treated
with artesunate as compared with quinine. Assuming this is generalizable to other settings, the higher cost of a
course of artesunate should not be considered a barrier for its implementation in the treatment of malaria.
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Background
Although falciparum malaria is an entirely preventable and
treatable disease, it caused an estimated 627,000 deaths in
2012 [1]. Malaria also has a devastating economic [2] and
social impact [3], being both a root cause and consequence
of poverty, contributing to the vicious cycle of poverty and
ill health. In endemic countries malaria is a common cause
of inpatient admissions and as access to health care
improves with economic development, a larger proportion
of patients with severe malaria are likely to be admitted in
time to receive potentially life-saving treatment. Providing
the most efficacious treatment to these patients will
improve survival.
Parenteral artesunate has been shown to be considerably
superior to quinine in the management of severe malaria,
with a reduction in mortality from 10.9% to 8.5% in
Africa [4] and from 22% to 15% in Asia [5]. Subsequent
cost-effectiveness analyses confirmed the economic
superiority of artesunate over quinine in the management
of malaria in both the African [6] and Asian [7] settings,
with an incremental cost per death averted of approximately
$150 in both settings, and is therefore highly cost-effective.
Despite these demonstrated benefits and WHO endorse-
ments, parenteral artesunate is the recommended first-line
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treatment for patients with severe malaria in a small
number of endemic and non-endemic countries, including
only two countries in sub-Saharan Africa [1]. One possible
reason for this slow uptake is the prima facie notion that
artesunate (US$ 2.3 per vial) is costlier than quinine (US$
0.2 per vial) [8] and would therefore pose a substantial
economic burden to healthcare systems. While previous
economic evaluations [6,7] found the costs of admission
for the two regimens were comparable, but they did not
benefit from detailed data on the resources used to
manage malaria admissions. This study estimates and
compares the costs of treating adult malaria inpatients
in a hospital on the Thai-Myanmar border with either
parenteral artesunate or quinine, building on a detailed
account of the resources used in caring for these patients.
Methods
Study site
This analysis used data from four studies conducted in Mae
Sot Hospital in Thailand from 1995 to 2001. The hospital is
located in Tak Province near the Thai-Myanmar border
and serves a predominantly rural population of Thai
farmers and Burmese and Karen displaced persons. Malaria
transmission in the area is seasonal and of low intensity
[9]. At the time of studies, 30% of the Thai population (18
million people) mostly from low socioeconomic groups as
well as the migrant population on the Thai Myanmar
border had no health insurance and no assured access to
free medical care, although exemptions were granted by
hospitals on a case-by-case basis. Out-of-pocket payment
accounted for 33% of total health expenditure in 2001[10].
Mae Sot Hospital has 420 beds and facilities for
haematology, biochemistry, microbiology, radiology,
ventilation, central line insertion, haemodialysis, and
peritoneal dialysis. Arterial blood gas and blood pH
determination of haemofiltration were not available.
Detailed resource use data were collected on specifically
designed forms in four studies in which patients were
randomized to artesunate or quinine treatment. In total,
resource use data were available for 100 patients. These
consisted of 42 patients recruited in a randomized control
trial on the treatment of severe falciparum malaria by either
parenteral artesunate or quinine [11]; 34 patients recruited
in a randomised trial of artesunate alone versus combined
artesunate and quinine (only those in the artesunate arm
were included in the current study) [12]; 19 patients
recruited to a study of red cell survival [13]; and five
patients recruited to a study of retinal findings in malaria
[14]. Ethical clearance for all these studies was approved by
the Ministry of Public Health, Government of Thailand.
Cost estimation
This analysis estimates patient-level direct medical costs
of managing inpatient falciparum malaria, calculated by
multiplying the quantities of resources used by their unit
costs (the ‘ingredients’ approach). Direct medical costs
included management of care, the costs of services, supplies
and equipment. Patients’ notes were reviewed and a list
made of all medications, fluids, equipment, laboratory tests,
and services provided. The hospital bills for each patient
were also entered into a database. If a bill listed more re-
sources than those recorded on the data collection forms,
the latter were used to determine the quantities of resources
used. Unit costs were taken from the 2008 hospital price list
as an approximation of the actual economic cost.
Total admission costs were broken down into five
categories: 1) medication; 2) intravenous fluids; 3)
disposables; 4) laboratory tests; and, 5) services. Medication
included the costs of all drugs used during admission
including anti-malarials, antibiotics and supportive
treatment. Intravenous fluid costs included all fluids
used during admission. Disposable equipment costs were
those of syringes, needles, cannulas, infusion sets, etc. All
investigations such as full blood count, serum biochemistry,
chest X-ray, and ECG were included in the laboratory costs.
Services included activities such as administration of fluids
and medications, as well as the overhead cost per admission
day in either the general wards or the ICU.
Other nurses and physicians activities that were not
amenable for inclusion in the costing but could affect
the relative time spent attending to patients in each
treatment group are summarised independently. These
consist of the number of times blood pressure, temperature,
pulse rates, and respiratory rates were measured, and
intake/output recordings. The number of pages in patient
notes written by nurses and physicians was also recorded as
an indication of nurse and physician time spent attending
to the patients.
All unit costs were obtained at 2008 prices in Thai
Baht (THB) and adjusted for inflation using a consumer
price index, and then converted to US dollars using the
2012 exchange rate (US$1 = 31 THB).
Statistical analysis
Patient-level data were entered in a Microsoft Excel
spreadsheet. All analyses were performed using R statistical
software, version 3.1 (Vienna, Austria). Costs for each
treatment group were summarized and stratified by severity.
Independent sample T-test was performed for hypothesis
testing of continuous variables. To deal with skewed cost
data and to reduce the effect of random sampling error,
non-parametric bootstrapping simulation was carried out
to select 1000 random samples with replacement from the
set of total admission costs in each treatment group.
Results
Of the 100 patients for whom data were available, the
majority of patients were male (75%) and the mean age
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was 32 years (IQR: 22–41 years). Fifty-seven percent of
the patients originated from Myanmar. Karen and
Burmese ethnic groups were most common, at 28 and
27%, respectively. Almost all patients of Myanmar origin
worked as general labourers. Among the 100 admissions,
59 were classified as severe malaria [15] and 41 had
uncomplicated malaria but required parenteral therapy
because of hyperparasitaemia or inability to take oral
medication.
Of all admitted malaria patients, 29 were treated
with parenteral quinine and 71 by parenteral artesunate
(the imbalanced distribution is due to inclusion of 34
patients treated with artesunate alone but not those
in the artesunate + quinine arm in the same study
[12]). The overall mortality rate amongst all patients
was 8% (95% CI 3-13%). In the artesunate group 4%
(95% CI 0-7%) died as compared with 17% (95% CI 3-30%)
of patients receiving quinine. Length of hospital stay was
different in the two groups, with a mean of seven days
(95% CI 5.3-9.3) in the quinine group as compared with
four days (95% CI 3.4-4.6) for artesunate. This difference
was apparent for patients with uncomplicated malaria
treated with quinine as compared with artesunate (4.1 vs
2.7 days; P = <0.001) but was not significantly different in
severe malaria patients (6.8 vs 5.4 days; P = 0.37). In
patients who died, the mean time from the start of
anti-malarial treatment to death was 70 hours; this
was shorter in quinine-treated patients at 27 hours
(95% CI 12–45) than artesunate-treated patients at
140 hours (95% CI 31–323).
While the cost of medication is lower in patients
receiving quinine, all other costs were considerably higher
in quinine-treated patients. The mean total admission cost
per patient treated with quinine was almost 30% higher
than for patients treated with artesunate, but this was not
statistically significant (P = 0.37). Table 1 presents the
individual component costs and full admission costs
for patients treated with artesunate or quinine, in total
and stratified by severity.
For patients with severe malaria the mean total admission
cost was similar in the two arms. In the quinine
group, the mean total admission cost per patient was
$298 (95% CI: 203–438) whilst for artesunate patients
it was US$284 (95% CI: 281–407) (P = 0.869). Figures 1
shows the proportional contribution of each component to
total admission costs. The main cost component was ser-
vices, accounting for almost 40% of total admission costs.
In addition to the activities included in services cost
category, patients receiving quinine required considerably
more nursing and physician time, as indicated by 1.5 to 3
times as many nursing monitoring activities. The time
spent by physicians attending to patients treated with
Table 1 Mean admission cost in US dollars in the treatment of falciparum malaria (2012)
Components Artesunate Quinine P-value
All malaria patients (n = 100)
Medication 63.1 (95% CI: 38.1-96.2) 32.1 (95% CI: 18.6-51.8) 0.077
Intravenous fluid 15.0 (95% CI: 10.7-19.6) 24.0 (95% CI: 17.1-32.1) 0.046
Disposables 6.6 (95% CI: 3.8-9.8) 15.2 (95% CI: 8.5-23.8) 0.015
Laboratory tests 37.5 (95% CI: 26.5-50.2) 74.6 (95% CI: 49.8-107.6) 0.008
Services 68.1 (95% CI: 47.6-92.4) 97.3 (95% CI: 61.8-146.4) 0.258
Total costs 190.3 (95% CI: 131.0-263.2) 243.1 (95% CI: 167.5-349.7) 0.375
Uncomplicated malaria (n = 41)
Medication 31.6 (95% CI 29.4-33.8) 16.5 (95% CI: 8.2-26.1) <0.001
Intravenous fluid 4.5 (95% CI: 3.7-5.4) 10.1 (95% CI: 7.6-13.3) 0.004
Disposables 1.5 (95% CI: 1.2-1.8) 2.9 (95% CI: 1.8-4.2) 0.002
Laboratory tests 14.2 (95% CI: 10.3-17.9) 24.6 (95% CI: 14.2-37.3) 0.125
Services 30.7 (95% CI: 23.9-30.0) 44.4 (95% CI: 31.4-56.1) 0.088
Total costs 82.5 (95% CI: 72.3-93.7) 98.5 (95% CI: 68.6-129.6) 0.353
Severe malaria (n = 59)
Medication 90.5 (95% CI: 44.4-148.6) 38.0 (95% CI: 20.4-65.3) 0.085
Intravenous fluid 24.0 (95% CI: 16.9-32.0) 29.3 (95% CI: 20.3-39.7) 0.412
Disposables 11.0 (95% CI: 6.1-16.5) 19.8 (95% CI: 11.4-30.3) 0.126
Laboratory tests 57.8 (95% CI: 39.9-80.1) 93.7 (95% CI: 62.3-139.3) 0.115
Services 100.6 (95% CI: 66.5-141) 117.4 (95% CI: 71.9-180.9) 0.636
Total costs 283.8 (95% CI: 181.3-407) 298.2 (95% CI: 203.6-438.7) 0.869
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quinine appeared to be higher as indicated by the larger
number of pages in their records. These differences are
explained by the longer duration of admission and were
not evident when compared on a per-day basis. Table 2
shows the breakdown in monitoring activities between the
two arms.
Discussion
There are numerous reasons that could explain the slow
uptake of artesunate in national treatment guidelines
and routine use, including the need for re-training and
establishing new procurement and distribution systems, as
well as clinician resistance to change. Given the untapped
potential gains offered by artesunate these all require
urgent attention. Here simply focus on the perception
that malaria admissions treated with artesunate might
be costlier as a barrier to implementation. While this
study confirms the higher cost of medication in patients
treated with artesunate, the study finds no evidence of
higher total admission costs, with some indication of cost
savings for patients treated with artesunate. This can be
explained to a great extent by the shorter time to
discharge and associated service costs as well as the
lower quantity of disposables and fluids required for
administering artesunate.
The estimated admission costs of inpatients with
malaria in this study are higher than those calculated in
previous studies [6,7]. In addition to the more detailed
methods used here that could capture a broader range of
inputs, the differences might be explained by the use of
hospital price list as unit costs, which could be higher than
their economic value. Despite total costs per admission for
both treatment groups being higher in this study, the dif-
ference between the treatment groups is non-significant,
with some indication of lower costs for patients treated
with artesunate. The incremental cost per DALY averted,
therefore, will remain very low, as indicated in other
studies, or potentially negative, implying that treatment
with artesunate dominates quinine being both less costly
and more effective.
Limitations
There are important limitations to this study. While it
benefits from detailed records of the resources used in
the two treatment arms, the unit costs applied to
these quantities were based on the hospital price list.
A cost/charge ratio was not available for this setting
to adjust prices to reflect their economic value. This
will not however affect the conclusion regarding the
relative costs of the two treatments, as long as the
variation in unit costs for the different items in other
settings is largely proportional.
Another limitation is that the resource use data were
collected around the late 1990s and in the context of
Figure 1 Cost components of treatment of inpatient falciparum malaria with quinine and artesunate.
Table 2 Mean number of monitoring activities per patient
receiving artesunate or quinine
Monitoring activities Artesunate Quinine P-value
Blood pressure 13 23 0.02
Pulse rate and temperature 20 31 0.08
Respiratory rate 21 31 0.09
Number of fluid intake/output
recordings
3 5 0.06
Number of pages of notes recorded
by nurses
4 6 0.14
Number of pages of notes recorded
by physicians
3 6 0.002
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clinical trials, therefore, their management might not
be entirely reflective of routine care in other settings.
This limitation is likely outweighed by the benefit of
randomization and head to head comparison of the two
treatments. Typically health systems do not implement
multiple first-line therapies and direct cost comparisons
cannot easily be made.
In terms of the statistical analysis the patients originated
from four different studies and ideally the analysis would
be stratified or controlled for accordingly. The sample size
however was too small to allow for this and while the
studies were different, the patients were cared for by the
same clinical team. The analysis of differences in length of
hospital stay between the two groups was limited and
did not account for competing risks associated with
differences in mortality. A more effective treatment
can in fact be ‘penalized’ with longer length of stay in
surviving patients (who would otherwise have died
early in their admission). More advanced statistical
analyses than those performed here can attempt to
tease these interacting factors apart, but given the
evidence regarding clinical superiority of artesunate
along with its cost-neutral or cost-saving implications
this would have limited added value.
Conclusion
This study finds no evidence for a difference in total
economic cost of care between inpatients treated with
quinine and those treated with artesunate, despite
substantial differences in drug prices. This analysis has
certain limitations including small sample size, the age of
the data used and the use of hospital price list as a proxy
for health system costs. Nevertheless, the global uptake
(or lack thereof) is of major importance in global health.
This study, with its limitations, suggests that financial
considerations should not prevent the switch from quinine
to artesunate for the treatment of malaria admissions.
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